Education
About Us
Working with TipRanks
Follow Us
Emyria Ltd (AU:EMD)
ASX:EMD
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$37.91M
Enterprise ValueAU$15.76M
Total Cash (Recent Filing)AU$10.50M
Total Debt (Recent Filing)AU$1.06M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,556,500
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.90M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue ModelEmyria’s dual revenue model blends recurring clinical-services income with episodic research-related fees. Clinics can provide steady patient-derived cash flows while trial and research contracts offer fee-for-service upside and partner optionality, supporting revenue resilience and strategic flexibility over the medium term.
Low Leverage And Equity Financing MixA debt-to-equity ratio of ~0.12 and a healthy equity ratio indicate manageable leverage, which reduces fixed financial obligations. This balance-sheet flexibility can support continued clinic operations and trial activity, allow calm execution of strategic plans, and provide capacity to raise capital without excessive debt strain.
Positioned In Growing Mental-health And Psychedelic ResearchEmyria’s focus on mental health, neuropsychiatry, and psychedelic-assisted therapy trials aligns it with structural demand growth and expanding scientific/regulatory interest. This positioning offers a durable addressable market for clinical services and long-term partnership or development opportunities, supporting strategic upside.
Bears Say
Revenue DeclineA 21.26% revenue decline highlights weakening top-line momentum. Sustained contraction reduces scale benefits, pressures clinic utilization economics, and limits funds available for trial investment or commercialization efforts. Reversing a multi-month revenue drop requires durable operational or contract wins to restore growth.
Persistent Negative Profit MarginsNegative gross, EBIT/EBITDA and net margins indicate core operations are loss-making. Persistent unprofitability constrains reinvestment, increases financing reliance, and suggests structural issues in pricing, cost control, or service mix that must be addressed to achieve sustainable profitability and long-term viability.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows show the company is burning cash and failing to convert reported results into liquidity. Persistent cash deficits limit runway, force dilution or external financing, and reduce flexibility to scale clinics or complete research programs without materially changing the cash generation profile.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.02 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$37.91M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 176 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,556,500 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-81.30%
Trailing 12-Months
Asset Growth
21.99%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Technical Analysis
Options Prices
Currently, No data available
---